There are eight new chemical entities in various stages of development that have generated four investigational new drug applications with the FDA. Since the payoff from these projects is far in the future, Ranbaxy's labs will continue pumping out generics, which net the company an aftertax margin of 16%.

FORBES: By the Numbers